Ebetaxel (Paclitaxel Ebewe) Indications/Uses

Ovarian carcinoma: In the first-line chemotherapy of ovarian cancer, paclitaxel is indicated for the treatment of patients with advanced carcinoma of the ovary or with residual disease (>1 cm) after initial laparotomy, in combination with cisplatin.
In the second-line chemotherapy of ovarian cancer, paclitaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of standard, platinum-containing therapy.
Breast carcinoma: In the adjuvant setting, paclitaxel is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with paclitaxel should be regarded as an alternative to extended AC therapy.
Paclitaxel is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express HER-2 at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable (see Precautions and Pharmacology: Pharmacodynamics under Actions).
As a single agent, paclitaxel is indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline-containing therapy.
Advanced non-small cell lung carcinoma: Paclitaxel, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiation therapy.
AIDS-related Kaposi's sarcoma: Paclitaxel is indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma (KS) who have failed prior liposomal anthracycline therapy.
Limited efficacy data supports this indication, a summary of the relevant studies is shown in Pharmacology: Pharmacodynamics under Actions.